Replies to post #192361 on Biotech Values

[north40000]

OCAT: Talk by its CSO, Dr.Robert Lanza, released earlier this week, in NYC in May 2015 before a distinguished Forum. The regenerative medicine activities, in both humans and animals, that he discusses continue to amaze me; particularly focus on eye treatments:

I am staying away from AAVL.

[DewDiligence]

AAVL +24% AH on phase-2a data in AMD:

http://finance.yahoo.com/news/avalanche-biotechnologies-inc-announces-positive-200200882.html

CC at 5pm ET.